VYVANSE 30 MG CHEWABLE TABLET

LISDEXAMFETAMINE DIMESYLATE
$12.3516per EA
High Outlier
DEA Schedule CII

Strength

30 mg/1

NDC

59417011701

Classification

Brand

Dosage Form

TABLET, CHEWABLE

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

LISDEXAMFETAMINE DIMESYLATE

Approval Type

New Drug (NDA)

FDA Application

NDA208510

On Market Since

1/28/2017

Pharmacological Classes

Central Nervous System Stimulant
Central Nervous System Stimulation

Price History

1W

0.0%

1M

-0.0%

3M

+0.0%

6M

-0.1%

1Y

-0.2%

3Y

+4.4%

5Y

+15.9%

All

+31.7%